Identification of PACE-1 as a novel therapeutic target for the treatment of prostate cancer

确定 PACE-1 作为治疗前列腺癌的新靶点

• 批准号: nhmrc : 1031228
• 负责人: Dr Ming Tat (Patrick) Ling
• 金额: $ 40.42万
• 依托单位: Queensland University of Technology
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/identification-pace-1-prostate-cancer/110794
• 关键词: Identification; PACE; novel; therapeutic; target

Advanced prostate cancer (PCa) remains the major therapeutic challenge since neither surgery nor systemic therapies are effective at this stage. Recently, we identified a protein called PACE-1 that is essential for PCa cell survival. We plan to investigate the roles of PACE-1 in the development and progression of prostate cancer. We will then test if PACE-1 inactivation alone or in combination with systemic cancer therapies will inhibit prostate tumor growth and disease progression.

晚期前列腺癌(PCA)仍然是主要的治疗挑战，因为在这个阶段手术或系统治疗都不有效。最近，我们发现了一种名为Pace-1的蛋白质，它对PCa细胞的生存至关重要。我们计划研究PACE-1在前列腺癌发生发展中的作用。然后，我们将测试Pace-1失活是否单独或与全身癌症治疗相结合，将抑制前列腺癌的生长和疾病进展。